- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04039607
A Study of Nivolumab in Combination With Ipilimumab in Participants With Advanced Hepatocellular Carcinoma (CheckMate 9DW)
August 21, 2026 updated by: Bristol-Myers Squibb
A Randomized, Multi-center, Phase 3 Study of Nivolumab in Combination With Ipilimumab Compared to Sorafenib or Lenvatinib as First-Line Treatment in Participants With Advanced Hepatocellular Carcinoma
The main purpose of this study is to compare the overall survival (OS) of nivolumab plus ipilimumab versus standard of care (SOC) (sorafenib or lenvatinib) in all randomized participants with advanced hepatocellular carcinoma (HCC) who have not received prior systemic therapy.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
732
Phase
- Phase 3
Expanded Access
Approved for sale to the public.
See expanded access record.
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Buenos Aires, Argentina, C1426ANZ
- Local Institution - 0136
-
San Miguel de Tucumán, Argentina, 4000
- Local Institution - 0058
-
-
Buenos Aires
-
Caba, Buenos Aires, Argentina, C1090AAS
- Local Institution - 0037
-
Pilar, Buenos Aires, Argentina, B1629ODT
- Local Institution - 0194
-
-
Santa Fe Province
-
Rosario, Santa Fe Province, Argentina, 2000
- Local Institution - 0282
-
-
-
-
New South Wales
-
Kogarah, New South Wales, Australia, 2217
- Local Institution - 0003
-
Liverpool, New South Wales, Australia, 1871
- Local Institution - 0038
-
Westmead, New South Wales, Australia, 2145
- Local Institution - 0002
-
-
Queensland
-
Birtinya, Queensland, Australia, 4560
- Local Institution - 0004
-
Herston, Queensland, Australia, 4029
- Local Institution - 0013
-
-
South Australia
-
Adelaide, South Australia, Australia, 5000
- Local Institution - 0009
-
-
Victoria
-
Clayton, Victoria, Australia, 3168
- Local Institution - 0019
-
Fitzroy, Victoria, Australia, 3065
- Local Institution - 0026
-
Melbourne, Victoria, Australia, 3004
- Local Institution - 0001
-
St Albans, Victoria, Australia, 3021
- Local Institution - 0020
-
-
-
-
-
Graz, Austria, 8036
- Local Institution - 0188
-
Klagenfurt, Austria, 9020
- Local Institution - 0065
-
Vienna, Austria, 1090
- Local Institution - 0186
-
-
Lower Austria
-
Sankt Pölten, Lower Austria, Austria, 3100
- Local Institution - 0114
-
Wiener Neustadt, Lower Austria, Austria, 2700
- Local Institution - 0057
-
-
-
-
-
Brussels, Belgium, 1070
- Local Institution - 0034
-
Federal District, Belgium, 72115700
- Local Institution - 0008
-
Ghent, Belgium, 9000
- Local Institution - 0124
-
Ghent, Belgium, 9000
- Local Institution - 0298
-
Haine-Saint-Paul, Belgium, 7100
- Local Institution - 0099
-
Leuven, Belgium, 3000
- Local Institution - 0064
-
Liège, Belgium, 4000
- Local Institution - 0104
-
-
-
-
-
Paranã, Brazil, 81520-060
- Local Institution - 0016
-
Rio de Janeiro, Brazil, 22793-080
- Local Institution - 0015
-
São Paulo, Brazil, 01246-000
- Local Institution - 0023
-
São Paulo, Brazil, 01323-900
- Local Institution - 0022
-
São Paulo, Brazil, 04038-034
- Local Institution - 0050
-
-
Espírito Santo
-
Vitória, Espírito Santo, Brazil, 29055-450
- Local Institution - 0278
-
-
Estado de Bahia
-
Salvador, Estado de Bahia, Brazil, 41253190
- Local Institution
-
Salvador, Estado de Bahia, Brazil, 41950-640
- Local Institution - 0061
-
-
Federal District
-
Brasília, Federal District, Brazil, 70200-730
- Local Institution - 0181
-
-
Rio Grande do Sul
-
Ijuí, Rio Grande do Sul, Brazil, 98700-000
- Local Institution - 0279
-
Pelotas, Rio Grande do Sul, Brazil, 96020-360
- Local Institution - 0060
-
-
São Paulo
-
Jaú, São Paulo, Brazil, 17210-120
- Local Institution - 0054
-
São José do Rio Preto, São Paulo, Brazil, 15090-000
- Hospital de Base de Sao Jose do Rio Preto
-
-
-
-
Alberta
-
Edmonton, Alberta, Canada, T6G 1Z2
- Local Institution - 0192
-
-
-
-
Araucania
-
Temuco, Araucania, Chile, 4780000
- Local Institution - 0296
-
-
Coquimbo Region
-
La Serena, Coquimbo Region, Chile, 1720430
- Local Institution - 0094
-
-
RM
-
Santiago, RM, Chile, 7630372
- Local Institution - 0283
-
-
Santiago Metropolitan
-
Santiago, Santiago Metropolitan, Chile
- Local Institution - 0095
-
Santiago, Santiago Metropolitan, Chile, 7710007
- Local Institution - 0024
-
Santiago, Santiago Metropolitan, Chile, 8380456
- Local Institution - 0156
-
-
Valparaiso
-
Viña del Mar, Valparaiso, Chile, 2520598
- Local Institution - 0012
-
Viña del Mar, Valparaiso, Chile, 2540402
- Local Institution - 0216
-
-
-
-
Anhui
-
Hefei, Anhui, China, 230601
- Local Institution - 0146
-
Hefei, Anhui, China, 230022
- Local Institution - 0120
-
-
Beijing Municipality
-
Beijing, Beijing Municipality, China, 100000
- Local Institution - 0175
-
Beijing, Beijing Municipality, China, 100142
- Local Institution - 0152
-
-
Fujian
-
Fuzhou, Fujian, China, 350002
- Local Institution - 0151
-
Fuzhou, Fujian, China, 350014
- Local Institution - 0121
-
-
Guangdong
-
Guangzhou, Guangdong, China, 510000
- Local Institution - 0125
-
Guangzhou, Guangdong, China, 510515
- Local Institution - 0150
-
-
Heilongjiang
-
Harbin, Heilongjiang, China, 150081
- Local Institution - 0135
-
-
Hunan
-
Changsha, Hunan, China, 410011
- Local Institution - 0059
-
Changsha, Hunan, China, 410006
- Local Institution - 0109
-
-
Jiangsu
-
Nanjing, Jiangsu, China, 210002
- Local Institution - 0130
-
-
Jiangxi
-
Nanchang, Jiangxi, China, 330006
- Local Institution - 0145
-
Nanchang, Jiangxi, China, 330019
- Local Institution - 0149
-
-
Jilin
-
Changchun, Jilin, China, 130021
- Local Institution - 0162
-
Changchun, Jilin, China, 130102
- Local Institution - 0166
-
-
Liaoning
-
Dalian, Liaoning, China, 116023
- Local Institution - 0131
-
Shenyang, Liaoning, China, 110004
- Local Institution - 0123
-
Shenyang, Liaoning, China, 110117
- Local Institution - 0132
-
-
Shaanxi
-
Xi'an, Shaanxi, China, 710038
- Local Institution - 0133
-
-
Shan3xi
-
Xi'an, Shan3xi, China, 710100
- Local Institution - 0307
-
Xi'an, Shan3xi, China, 710061
- Local Institution - 0147
-
-
Shandong
-
Qingdao, Shandong, China, 266000
- Local Institution - 0153
-
-
Shanghai Municipality
-
Shanghai, Shanghai Municipality, China, 200032
- Local Institution - 0134
-
-
Sichuan
-
Chongqing, Sichuan, China, 400030
- Local Institution - 0179
-
-
Zhejiang
-
Hangzhou, Zhejiang, China, 310022
- Local Institution - 0107
-
Hangzhou, Zhejiang, China, 310000
- Local Institution - 0108
-
-
-
-
-
Brno, Czechia, 60200
- Local Institution
-
-
Prague
-
Prague, Prague, Czechia, 14059
- Local Institution - 0274
-
-
-
-
-
Amiens, France, 80054
- Local Institution - 0068
-
Caen, France, 14033
- Local Institution - 0116
-
Clichy, France, 92110
- Local Institution - 0069
-
Dijon, France, 21000
- Local Institution - 0138
-
Grenoble, France, 38043
- Local Institution - 0081
-
Lyon, France, 69004
- Local Institution - 0070
-
Marseille, France, 13009
- Local Institution
-
Montpellier, France, 34295
- Local Institution - 0082
-
Nice, France, 6202
- Local Institution - 0067
-
Pessac, France, 33604
- Local Institution - 0025
-
Poitiers, France, 86021
- Local Institution - 0137
-
Toulouse, France, 31059
- Local Institution - 0042
-
Vandœuvre-lès-Nancy, France, 54500
- Local Institution - 0071
-
Villejuif, France, 94800
- Local Institution - 0051
-
-
-
-
-
Bonn, Germany, 53127
- Local Institution - 0231
-
Cologne, Germany, 50937
- Local Institution - 0028
-
Essen, Germany, 45147
- Local Institution - 0052
-
Freiburg im Breisgau, Germany, 79106
- Local Institution - 0185
-
Hamburg, Germany, 20246
- Local Institution - 0006
-
Hanover, Germany, 30625
- Local Institution - 0102
-
Leipzig, Germany, 04103
- Local Institution - 0118
-
Mainz, Germany, 55131
- Local Institution - 0031
-
Mannheim, Germany, 68167
- Local Institution - 0056
-
München, Germany, 81675
- Local Institution
-
North Rhine-Westphalia, Germany, 45136
- Local Institution - 0053
-
-
Hesse
-
Frankfurt am Main, Hesse, Germany, 60590
- Local Institution - 0005
-
-
-
-
-
Hong Kong, Hong Kong, 999077
- Local Institution - 0036
-
Hong Kong, Hong Kong
- Local Institution - 0032
-
-
-
-
-
Candiolo, Italy, 10060
- Local Institution - 0084
-
Milan, Italy, 20122
- Local Institution - 0039
-
Novara, Italy, 28100
- Local Institution - 0100
-
Padova, Italy, 35128
- Local Institution - 0219
-
Parma, Italy, 43126
- Local Institution - 0033
-
Roma, Italy, 00128
- Local Institution - 0112
-
Rome, Italy, 00168
- Local Institution - 0079
-
Siena, Italy, 53100
- Local Institution - 0111
-
Vicenza, Italy, 36100
- Local Institution - 0044
-
-
Forli-Cesena
-
Meldola, Forli-Cesena, Italy, 47014
- Local Institution - 0110
-
-
Milano
-
Rozzano, Milano, Italy, 20089
- Local Institution - 0101
-
-
-
-
-
Chiba, Japan, 260-8677
- Local Institution - 0204
-
Fukuoka, Japan, 830-0011
- Local Institution - 0178
-
Hiroshima, Japan, 7348551
- Local Institution - 0177
-
Sapporo, Japan, 0600033
- Local Institution - 0155
-
-
Chiba
-
Kashiwa-shi, Chiba, Japan, 2778577
- Local Institution - 0193
-
-
Ehime
-
Matsuyama, Ehime, Japan, 790-0024
- Local Institution - 0203
-
-
Ishikawa-ken
-
Kanazawa, Ishikawa-ken, Japan, 920-8641
- Local Institution - 0176
-
-
Kanagawa
-
Yokohama, Kanagawa, Japan, 241-8515
- Local Institution - 0262
-
Yokohama, Kanagawa, Japan, 2320024
- Local Institution - 0200
-
-
Kyoto
-
Kyoto, Kyoto, Japan, 602-8566
- Local Institution - 0189
-
-
Nara
-
Kashihara, Nara, Japan, 634-8522
- Local Institution - 0261
-
-
Osaka
-
Abeno-ku, Osaka, Japan, 5458586
- Local Institution - 0263
-
Sayama, Osaka, Japan, 5898511
- Local Institution - 0127
-
-
Saga-ken
-
Saga, Saga-ken, Japan, 8408571
- Local Institution - 0281
-
-
Saitama
-
Iruma-gun, Saitama, Japan, 3500495
- Local Institution - 0258
-
-
Shizuoka
-
Izunokuni-shi, Shizuoka, Japan, 410-2295
- Local Institution - 0259
-
-
Tokyo
-
Minato, Tokyo, Japan, 105-8470
- Local Institution - 0128
-
Minato-ku, Tokyo, Japan, 105-8470
- Local Institution - 0122
-
Mitaka, Tokyo, Japan, 181-8611
- Local Institution - 0201
-
Musashino-shi, Tokyo, Japan, 180-8610
- Local Institution - 0199
-
-
-
-
-
Auckland, New Zealand, 1023
- Local Institution - 0047
-
-
Canterbury
-
Christchurch, Canterbury, New Zealand, 8011
- Local Institution - 0286
-
-
-
-
-
Gdansk, Poland, 80219
- Local Institution - 0148
-
Otwock, Poland, 05-400
- Local Institution - 0049
-
Warsaw, Poland, 02-034
- Local Institution - 0092
-
-
-
-
-
Rio Piedras, Puerto Rico, 00935
- Local Institution - 0289
-
San Juan, Puerto Rico, 00927-4308
- Local Institution - 0035
-
-
-
-
-
Bucharest, Romania, 022328
- Local Institution - 0164
-
Cluj-Napoca, Romania, 400015
- Local Institution - 0165
-
Craiova, Romania, 200385
- Local Institution
-
Timișoara, Romania, 300166
- Local Institution - 0163
-
-
Dolj
-
Craiova, Dolj, Romania, 200542
- Local Institution - 0103
-
-
-
-
-
Arkhangelsk, Russia, 163045
- Local Institution - 0029
-
Barnaul, Russia, 656045
- Local Institution - 0066
-
Chelyabinsk, Russia, 454087
- Local Institution - 0074
-
Moscow, Russia, 115478
- Local Institution - 0007
-
Pyatigorsk, Russia, 357502
- Local Institution - 0072
-
Saint Petersburg, Russia, 197758
- Local Institution - 0075
-
Saint Petersburg, Russia, 198255
- Local Institution - 0091
-
Sochi, Russia, 354057
- Local Institution - 0073
-
-
-
-
-
Singapore, Singapore, 258499
- Local Institution - 0017
-
Singapore, Singapore, 308442
- Local Institution - 0174
-
Singapore, Singapore, 168583
- Local Institution - 0048
-
-
-
-
-
Busan, South Korea, 49241
- Local Institution - 0142
-
Gyeonggi-do, South Korea, 010408
- Local Institution - 0097
-
Gyeongsangnam-do, South Korea, 050612
- Local Institution - 0098
-
Seoul, South Korea, 03722
- Local Institution - 0141
-
Seoul, South Korea, 05505
- Local Institution - 0140
-
Seoul, South Korea, 06351
- Local Institution - 0139
-
-
Gyeonggi-do
-
Seongnam-si, Gyeonggi-do, South Korea, 13496
- Local Institution - 0143
-
-
Seoul
-
Guro-gu, Seoul, South Korea, 8308
- Local Institution - 0167
-
Jongno-gu, Seoul, South Korea, 03080
- Local Institution - 0062
-
-
-
-
-
Barcelona, Spain, 08035
- Local Institution - 0297
-
Barcelona, Spain, 08036
- Local Institution - 0055
-
Barcelona, Spain, 08908
- Local Institution - 0089
-
Córdoba, Spain, 14004
- Local Institution - 0090
-
El Palmar, Spain, 30120
- Local Institution - 0087
-
Madrid, Spain, 28007
- Local Institution - 0041
-
Madrid, Spain, 28028
- Local Institution - 0093
-
Madrid, Spain, 28035
- Local Institution - 0290
-
Majadahonda, Spain, 28222
- Local Institution - 0045
-
Pamplona, Spain, 31008
- Local Institution - 0085
-
Santander, Spain, 39008
- Local Institution - 0088
-
Zaragoza, Spain, 50009
- Local Institution - 0040
-
-
-
-
-
Bern, Switzerland, 3010
- Local Institution - 0063
-
-
-
-
-
Kaohsiung City, Taiwan, 807
- Local Institution - 0272
-
Kaohsiung City, Taiwan, 83301
- Local Institution - 0096
-
Taichung, Taiwan, 40447
- Local Institution - 0105
-
Taichung, Taiwan, 40705
- Local Institution - 0271
-
Tainan, Taiwan, 704
- Local Institution - 0168
-
Tainan, Taiwan, 736
- Local Institution - 0270
-
Taipei, Taiwan, 10002
- Local Institution - 0144
-
Taipei, Taiwan, 11266
- Local Institution - 0078
-
Taoyuan, Taiwan, 333
- Local Institution - 0173
-
-
-
-
-
Edinburgh, United Kingdom, EH4 2XU
- Local Institution - 0160
-
London, United Kingdom, SE5 9RS
- Local Institution - 0129
-
-
Greater London
-
London, Greater London, United Kingdom, W12 OHS
- Local Institution - 0171
-
-
Surrey
-
Guildford, Surrey, United Kingdom, GU2 7XX
- Local Institution - 0154
-
-
-
-
Arizona
-
Tucson, Arizona, United States, 85719
- Local Institution - 0292
-
-
California
-
Coronado, California, United States, 92118
- Local Institution - 0288
-
Duarte, California, United States, 91010-3012
- Local Institution - 0157
-
-
District of Columbia
-
Washington D.C., District of Columbia, United States, 20007
- Local Institution - 0077
-
-
Kentucky
-
Louisville, Kentucky, United States, 40217
- Local Institution - 0027
-
-
Maryland
-
Baltimore, Maryland, United States, 21287
- Local Institution - 0190
-
-
Michigan
-
Ann Arbor, Michigan, United States, 48105
- Local Institution
-
Detroit, Michigan, United States, 48202
- Local Institution - 0018
-
-
New Jersey
-
Newark, New Jersey, United States, 07103
- Local Institution - 0295
-
-
Ohio
-
Toledo, Ohio, United States, 43623
- Local Institution - 0043
-
-
Pennsylvania
-
Pittsburgh, Pennsylvania, United States, 15212
- Local Institution - 0284
-
-
Texas
-
Dallas, Texas, United States, 75203
- Local Institution - 0304
-
Houston, Texas, United States, 77030
- Local Institution - 0202
-
Lubbock, Texas, United States, 79410
- Local Institution - 0046
-
-
Utah
-
Salt Lake City, Utah, United States, 84106
- Local Institution - 0172
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Participants must have a diagnosis of HCC based on histological confirmation
- Participants must have an advanced HCC
- Participants must have at least one Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 measurable previously untreated lesion
- Child-Pugh score 5 or 6
- Eastern Cooperative Oncology Group (ECOG) performance status(PS) 0 or 1
Exclusion Criteria:
- Known fibrolamellar HCC, sarcomatoid HCC, or mixed cholangiocarcinoma and HCC
- Prior liver transplant
- Episodes of hepatic encephalopathy (greater than or equal to [>=] Grade 2) within 12 months prior to randomization
- Active brain metastases or leptomeningeal metastases
Other protocol-defined inclusion/exclusion criteria apply.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Nivolumab + Ipilimumab
|
Participants will receive nivolumab as intravenous (IV) infusion.
Participants will receive ipilimumab as IV infusion.
|
|
Active Comparator: Sorafenib/lenvatinib
|
Participants will receive sorafenib as oral tablets.
Participants will receive lenvatinib as oral capsules.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Overall Survival (OS)
Time Frame: Up to 4 years
|
Up to 4 years
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Duration of Response (DOR)
Time Frame: Up to 4 years
|
Up to 4 years
|
|
Objective Response Rate (ORR)
Time Frame: Up to 4 years
|
Up to 4 years
|
|
Time to Symptom Deterioration (TTSD)
Time Frame: Up to 4 years
|
Up to 4 years
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Study Director: Bristol-Myers Squibb, Bristol-Myers Squibb
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
General Publications
- Yau T, Galle PR, Decaens T, Sangro B, Qin S, da Fonseca LG, Karachiwala H, Blanc JF, Park JW, Gane E, Pinter M, Pena AM, Ikeda M, Tai D, Santoro A, Pizarro G, Chiu CF, Schenker M, He A, Chon HJ, Wojcik-Tomaszewska J, Verset G, Wang QQ, Stromko C, Neely J, Singh P, Jimenez Exposito MJ, Kudo M; CheckMate 9DW investigators. Nivolumab plus ipilimumab versus lenvatinib or sorafenib as first-line treatment for unresectable hepatocellular carcinoma (CheckMate 9DW): an open-label, randomised, phase 3 trial. Lancet. 2025 May 24;405(10492):1851-1864. doi: 10.1016/S0140-6736(25)00403-9. Epub 2025 May 8.
- Yau T, Galle PR, Decaens T, Sangro B, Qin S, da Fonseca LG, Karachiwala H, Blanc JF, Park JW, Gane E, Pinter M, Matilla Pena A, Ikeda M, Tai D, Santoro A, Pizarro G, Chiu CF, Schenker M, He A, Chon HJ, Wojcik-Tomaszewska J, Verset G, Wang QQ, Stromko C, Neely J, Singh P, Jimenez Exposito MJ, Kudo M. A plain language summary of the CheckMate 9DW study: nivolumab in combination with ipilimumab for unresectable hepatocellular carcinoma (advanced liver cancer). Future Oncol. 2026 Apr;22(10):1135-1152. doi: 10.1080/14796694.2026.2651375. Epub 2026 Apr 14.
- Huynh JC, Cho M, Monjazeb A, Al-Obeidi E, Singh A, Tam K, Lara F, Martinez A, Garcia L, Kim EJ. Phase I/II trial of BMS-986,205 and nivolumab as first line therapy in hepatocellular carcinoma. Invest New Drugs. 2024 Feb;42(1):35-43. doi: 10.1007/s10637-023-01416-w. Epub 2023 Dec 1.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
September 30, 2019
Primary Completion (Actual)
July 9, 2026
Study Completion (Actual)
July 9, 2026
Study Registration Dates
First Submitted
July 30, 2019
First Submitted That Met QC Criteria
July 30, 2019
First Posted (Actual)
July 31, 2019
Study Record Updates
Last Update Posted (Actual)
August 25, 2026
Last Update Submitted That Met QC Criteria
August 21, 2026
Last Verified
August 1, 2026
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Neoplasms by Site
- Neoplasms
- Neoplasms by Histologic Type
- Digestive System Neoplasms
- Digestive System Diseases
- Liver Diseases
- Neoplasms, Glandular and Epithelial
- Adenocarcinoma
- Liver Neoplasms
- Carcinoma
- Carcinoma, Hepatocellular
- Amino Acids, Peptides, and Proteins
- Proteins
- Organic Chemicals
- Pyridines
- Heterocyclic Compounds, 1-Ring
- Heterocyclic Compounds
- Hydrocarbons
- Hydrocarbons, Cyclic
- Hydrocarbons, Aromatic
- Amides
- Antibodies, Monoclonal, Humanized
- Antibodies, Monoclonal
- Antibodies
- Immunoglobulins
- Immunoproteins
- Blood Proteins
- Serum Globulins
- Globulins
- Benzene Derivatives
- Urea
- Acids, Heterocyclic
- Phenylurea Compounds
- Niacinamide
- Nicotinic Acids
- Sorafenib
- Nivolumab
- Ipilimumab
- lenvatinib
Other Study ID Numbers
- CA209-9DW
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
YES
IPD Plan Description
BMS will provide access to individual anonymized participant data upon request from qualified researchers, and subject to certain criteria.
Additional information regarding Bristol Myer Squibb's data sharing policy and process can be found at https://www.bms.com/researchers-and-partners/clinical-trials-and-research.html
IPD Sharing Time Frame
See Plan Description
IPD Sharing Access Criteria
See Plan Description
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
- SAP
- CSR
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.